BioTuesdays

Tag - Stifel

ViewRay Logo
Markets

Stifel starts ViewRay at buy; PT $7

Stifel initiated coverage of ViewRay (NASDAQ:VRAY) with a “buy” rating and price target of $7, reflecting a multiple of 8.3 times estimated 2023 revenue of $130-million. The stock closed at $4.46 on Jan. 24. “We see...

January 25, 2022
Apollo Endosurgery
Markets

Stifel starts Apollo Endosurgery at buy; PT $12

Stifel launched coverage of Apollo Endosurgery (NASDAQ:APEN) with a “buy” rating and $12 price target. The stock closed at $8.59 on Dec. 8. Apollo Endosurgery is a medical technology company focused on design...

December 9, 2021
Bolt-Biotherapeutics
Markets

Stifel cuts Bolt Biotherapeutics PT to $19 from $34

Stifel reduced its price target for Bolt Biotherapeutics (NASDAQ:BOLT) to $19 from $34, but maintained its “buy” rating, after the company presented interim clinical data from an ongoing Phase 1/2 study of BDC-1001, its...

December 6, 2021
Markets

Analysts start Sonendo at buy, OW

Analyst for Stifel and Piper Sandler initiated coverage of Sonendo (NYSE:SONX) with “buy” and “overweight” ratings and prices targets of $16 and $17, respectively. The stock closed at $10.55 on Nov. 22. Sonendo is a...

November 23, 2021
Deciphera Pharma
Markets

Stifel cuts Deciphera Pharma to hold; PT to $10 from $60

Stifel downgraded Deciphera Pharmaceuticals (NASDAQ:DCPH) to “hold” from “buy” and slashed its price target to $10 from $60 after the failure of the company’s Qinlock in 2L gastrointestinal stromal tumor (GIST).  Shares...

November 8, 2021
Affimed
Markets

Stifel starts Affimed at buy; PT $12

Stifel launched coverage of Affimed NV (NASDAQ:AFMD) with a “buy” rating and price target of $12. The stock closed at $5.85 on Sept. 29. Affimed is a clinical-stage biotechnology company focused on bispecific antibody...

September 30, 2021
Markets

Stifel starts Repare Therapeutics at buy; PT $48

Stifel launched coverage of Repare Therapeutics (NASDAQ:RPTX) with a “buy” rating and $48 price target. The stock finished at $28.48 on Sept. 22. Analyst Benjamin Burnett, Ph.D., writes that his rating is largely...

September 23, 2021
Kinnate-Biopharma
Markets

Stifel starts Kinnate Biopharma at buy; PT $32

Stifel launched coverage of Kinnate Biopharma (NASDAQ:KNTE) with a “buy” rating and $32 price target. The stock closed at $23.44 on Sept. 22. “Our positive thesis is based on the belief that the Phase 1 data for KIN...

September 23, 2021
Pennant Group logo
Markets

Stifel starts Pennant Group at buy; PT $37

Stifel launched coverage of Pennant Group (NASDAQ:PNTG) with a “buy” rating and price target of $37. The stock closed at $29.88 on Sept. 20. “We believe home health and hospice are the fastest-growing areas of...

September 20, 2021